<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02488629</url>
  </required_header>
  <id_info>
    <org_study_id>SCB01A-21</org_study_id>
    <nct_id>NCT02488629</nct_id>
  </id_info>
  <brief_title>Study of SCB01A in Patient With Head and Neck Cancer</brief_title>
  <official_title>An Open-Label, Phase II Study to Evaluate SCB01A in Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer Who Have Received Platinum-Based Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SynCore Biotechnology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SynCore Biotechnology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of SCB01A in head and neck cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed to evaluate the safety and efficacy of SCB01A in patients with
      recurrent or metastatic squamous cell carcinoma in head and neck.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the disease control rate</measure>
    <time_frame>9 weeks from 1st drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the overall survival rate</measure>
    <time_frame>an expected average of 36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the progression-free survival</measure>
    <time_frame>an expected average of 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as assessed using EORTC QLQ C30 and H&amp;N35 questionnaires</measure>
    <time_frame>an expected average of 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>SCB01A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This study is a single arm, open-label, Phase II trial</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCB01A</intervention_name>
    <description>This study is a single arm, open-label, Phase II trial</description>
    <arm_group_label>SCB01A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Confirmed squamous cell carcinoma of head and neck

          2. Patients with nonresectable, unfeasible radiotherapy, recurrent or metastatic
             carcinoma, after previous treatment with platinum agent.

          3. At least one measurable tumor lesion according to RECIST

          4. Suitable Eastern Cooperative Oncology Group (ECOG) performance status

          5. All eligible patients of childbearing potential have to use effective contraception

          6. Signed informed consent before enrolment

        Exclusion Criteria:

          1. Receiving Chemotherapy, radiation therapy, major surgery or investigational agents

          2. Severe pulmonary obstructive or restrictive disease

          3. Uncontrolled inflammatory disease

          4. Clinically significant cardiac disease

          5. Results of laboratory tests

          6. Pregnancy or nursing status

          7. Known hypersensitivity to any component of SCB01A

          8. History of exposure to SCB01A or its analogues

          9. History of malignancy other than head and neck cancer

         10. History of active or significant neurological disorder or psychiatric disorder

         11. Any other reason the investigator deems the patient to be unsuitable for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hui-Hung Wang, MSc</last_name>
    <role>Study Director</role>
    <affiliation>SynCore Biotechnology Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Keelung Chang Gung Memorial Hospital &amp; lovers lake branch</name>
      <address>
        <city>Keelung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MacKay Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linkou Chang Gung Memorial Hospital</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2015</study_first_submitted>
  <study_first_submitted_qc>July 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2015</study_first_posted>
  <last_update_submitted>October 18, 2017</last_update_submitted>
  <last_update_submitted_qc>October 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Head and neck squamous cell carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

